CHANGES IN METABOLIC AND RENAL SYSTEM AFTER HCV CLEARANCE IN CHRONIC VIRAL HEPATITIS PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS

H PASHA; AT TARIQ; A BANGASH; M SALIM; T MOHIUDIN

doi:10.54112/bcsrj.v2024i1.837

Authors

H PASHA Department of Emergency, Shifa International Hospital Islamabad, Pakistan
AT TARIQ Department of Internal Medicine, Shifa International Hospital Islamabad, Pakistan
A BANGASH Department of Emergency, Shifa International Hospital Islamabad, Pakistan
M SALIM Department of Emergency, Shifa International Hospital Islamabad, Pakistan
T MOHIUDIN Department of Emergency, Shifa International Hospital Islamabad, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.837

Keywords:

Direct antivirals, Hepatitis C, Metabolism, Renal

Abstract

Chronic hepatitis C infection is associated with metabolic and renal abnormalities, with direct antiviral agents (DAAs) offering a promising treatment approach. However, the influence of hepatitis C virus (HCV) clearance on metabolic and renal parameters in these patients remains underexplored. Objective: This study aimed to assess the impact of HCV clearance on the metabolic and renal system of chronic hepatitis C patients treated with direct antiviral agents. Methods: A prospective study was conducted at the Department of Medicine, Shifa Hospital, Islamabad, from January 2022 to January 2024. A total of 323 patients with chronic hepatitis C treated with DAAs were included. Hepatic and renal function tests were recorded before treatment, post-treatment, and 6-month follow-up. Insulin resistance (IR) and B-cell function were evaluated using the homeostatic model assessment (HOMA). All patients received DAAs treatment, with or without ribavirin. Statistical analysis was performed using appropriate methods. Results: Following HCV clearance, both groups exhibited a significant decrease in fasting glucose and insulin levels and improvements in HOMA-IR values. Additionally, decreased creatinine levels and increased glomerular filtration rate (GFR) indicated enhanced renal function. Sustained virologic response (SVR) emerged as an independent predictor of improvement in GFR and HOMA-IR. Conclusion: HCV clearance in chronic hepatitis C infection, achieved through treatment with direct antiviral agents, leads to notable improvements in renal and metabolic parameters. These findings underscore the importance of achieving SVR in managing chronic hepatitis C.

Downloads

Download data is not yet available.

References

Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel M. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol belg. 2021;84(4):637-56.

Cacoub P, Comarmond C, editors. Considering hepatitis C virus infection as a systemic disease. Seminars in Dialysis; 2019: Wiley Online Library.

Ambachew S, Eshetie S, Geremew D, Endalamaw A, Melku M. Prevalence of type 2 diabetes mellitus among hepatitis C virus-infected patients: a systematic review and meta-analysis protocol. Systematic Reviews. 2019;8:1-4.

Elgretli W, Chen T, Kronfli N, Sebastiani G. Hepatitis C virus-lipid interplay: pathogenesis and clinical impact. Biomedicines. 2023;11(2):271.

Henson JB, Sise ME, editors. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Seminars in dialysis; 2019: Wiley Online Library.

Sise ME, Chute DF, Oppong Y, Davis MI, Long JD, Silva ST, et al. Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease. Kidney international. 2020;97(1):193-201.

Bolarinwa OA. Sample size estimation for health and social science researchers: The principles and considerations for different study designs. Nigerian Postgraduate Medical Journal. 2020;27(2):67-75.

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes—2023. Diabetes care. 2023;46(Supplement_1):S19-S40.

Lewandowski KC, Skowrońska-Jóźwiak E, Łukasiak K, Gałuszko K, Dukowicz A, Cedro M, et al. How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance (Belfiore) index models. Archives of Medical Science. 2019;15(3):613-8.

Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series☆. Journal of hepatology. 2020;73(5):1170-218.

Cheng C-H, Chu C-Y, Chen H-L, Lin I-T, Wu C-H, Lee Y-K, et al. Virus elimination by direct-acting antiviral agents impacts glucose homeostasis in chronic hepatitis C patients. Frontiers in Endocrinology. 2022;12:799382.

Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, et al. A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses. 2021;13(11):2249.

Adinolfi LE, Petta S, Fracanzani AL, Nevola R, Coppola C, Narciso V, et al. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: a prospective study. Diabetes, Obesity and Metabolism. 2020;22(12):2408-16.

Graf C, Welzel T, Bogdanou D, Vermehren J, Beckel A, Bojunga J, et al. Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis. Journal of clinical medicine. 2020;9(9):2702.

Mada PK, Malus ME, Parvathaneni A, Chen B, Castano G, Adley S, et al. Impact of treatment with direct acting antiviral drugs on glycemic control in patients with hepatitis C and diabetes mellitus. International Journal of Hepatology. 2020;2020.

Nazar T, Aziz B, Ghias M. Treatment Response of Direct Acting Antiviral Agents on Glycemic Control in Diabetic Patients with Chronic Hepatitis C. PJMHS. 2019;13(1):169-72.

Elhelbawy M, Abdel-Razek W, Alsebaey A, Hashim M, Elshenawy H, Waked I. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. European Journal of Gastroenterology & Hepatology. 2019;31(1):16-23.

Yosef T, Ibrahim WA, El-Ghandour A, Attia S, El-Nakeep S. Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity. The Egyptian Journal of Internal Medicine. 2021;33:1-14.

Chaudhury CS, Sheehan J, Chairez C, Akoth E, Gross C, Silk R, et al. No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV. The Journal of infectious diseases. 2018;217(1):47-50.

Carnovale C, Pozzi M, Dassano A, D’Addio F, Gentili M, Magni C, et al. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. Acta diabetologica. 2019;56:341-54.

El Badry MM, Ali DA, Eltaweel NH, Abdel-Wahed MA. Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control. Egyptian Liver Journal. 2020;10:1-7.

Villani R, Di Cosimo F, Romano AD, Sangineto M, Serviddio G. Serum lipid profile in HCV patients treated with direct-acting antivirals: A systematic review and meta-analysis. Scientific Reports. 2021;11(1):13944.

Iossa D, Vitrone M, Gagliardi M, Falco E, Ragone E, Zampino R, et al. Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment. Annals of Translational Medicine. 2021;9(1).

Özdoğan O, Yaraş S, Ateş F, Üçbilek E, Sezgin O, Altıntaş E. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent? The Turkish Journal of Gastroenterology. 2020;31(5):384.

Pérez de José A, Carbayo J, Pocurull A, Bada-Bosch T, Cases Corona CM, Shabaka A, et al. Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study. Clinical Kidney Journal. 2021;14(2):586-92.

Coppola N, Portunato F, Buonomo AR, Staiano L, Scotto R, Pinchera B, et al. Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. Journal of Nephrology. 2019;32:763-73.